DOP2017000134A - Formulaciones inyectables de paracetamol - Google Patents

Formulaciones inyectables de paracetamol

Info

Publication number
DOP2017000134A
DOP2017000134A DO2017000134A DO2017000134A DOP2017000134A DO P2017000134 A DOP2017000134 A DO P2017000134A DO 2017000134 A DO2017000134 A DO 2017000134A DO 2017000134 A DO2017000134 A DO 2017000134A DO P2017000134 A DOP2017000134 A DO P2017000134A
Authority
DO
Dominican Republic
Prior art keywords
paracetamol
injectable formulations
administration
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DO2017000134A
Other languages
English (en)
Inventor
R Patel Ketan
r patel Milan
J Shah Prakashchandra
K Patel Asheel
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55022620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2017000134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of DOP2017000134A publication Critical patent/DOP2017000134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a inyecciones intravenosas de bajo volumen de paracetamol o su sal farmacéuticamente aceptable y el método de preparación del mismo. Las formulaciones proporcionan una alta concentración de paracetamol o su sal farmacéuticamente aceptable en un sistema disolvente de la presente invención que puede administrarse no sólo a través de la vía de infusión intramuscular e intravenosa, sino también para la administración de bolo IV lento después de la dilución con fluidos acuosos hasta el volumen final de no más de 20 ml. Estas formulaciones inyectables permanecen estables y también son adecuadas para administración a través de una vía intravenosa lenta con efectos secundarios minimizados (tales como flebitis, dolor, etc.)
DO2017000134A 2014-12-20 2017-06-09 Formulaciones inyectables de paracetamol DOP2017000134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4102MU2014 2014-12-20

Publications (1)

Publication Number Publication Date
DOP2017000134A true DOP2017000134A (es) 2017-09-15

Family

ID=55022620

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000134A DOP2017000134A (es) 2014-12-20 2017-06-09 Formulaciones inyectables de paracetamol

Country Status (28)

Country Link
US (1) US20180000940A1 (es)
EP (1) EP3233055A1 (es)
JP (1) JP2017538762A (es)
KR (1) KR20170099911A (es)
CN (1) CN107205924A (es)
AR (1) AR103188A1 (es)
AU (1) AU2015365533A1 (es)
BR (1) BR112017012975B1 (es)
CA (1) CA2969303A1 (es)
CL (1) CL2017001629A1 (es)
CO (1) CO2017006268A2 (es)
CU (1) CU20170088A7 (es)
DO (1) DOP2017000134A (es)
EA (1) EA201791409A1 (es)
EC (1) ECSP17038668A (es)
IL (1) IL252729A0 (es)
JO (1) JO3689B1 (es)
MA (1) MA40599A1 (es)
MD (1) MD20170071A2 (es)
MX (1) MX2017008264A (es)
PE (1) PE20171305A1 (es)
PH (1) PH12017501005A1 (es)
SG (1) SG11201704435PA (es)
TN (1) TN2017000232A1 (es)
TW (1) TWI649097B (es)
UA (1) UA122136C2 (es)
UY (1) UY36466A (es)
WO (1) WO2016097899A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107229455B (zh) 2016-03-24 2019-09-17 阿里巴巴集团控股有限公司 一种业务处理方法、装置及系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
IT1301976B1 (it) * 1998-07-31 2000-07-20 Angelini Ricerche Spa Composizione farmaceutica iniettabile a base di paracetamolo
IT1313579B1 (it) 1999-07-30 2002-09-09 Acraf Composizione farmaceutica liquida a base di paracetamolo.
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
EA200702646A1 (ru) * 2005-05-27 2008-06-30 Панацея Биотек Лтд. Композиции для инъекций и способ приготовления данных композиций
PT1973527E (pt) * 2005-12-15 2010-01-04 Acusphere Inc Processos de produção de formulações farmacêuticas à base de partículas destinadas a administração parentérica
EP2170313A2 (en) 2007-06-18 2010-04-07 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
US20110015273A1 (en) 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
KR20110067103A (ko) * 2008-10-09 2011-06-21 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 파라세타몰을 포함하는 액체 약학적 제제
WO2012001494A2 (en) * 2010-06-30 2012-01-05 Troikaa Pharmaceuticals Limited Pharmaceutical compositions comprising paracetamol and process for preparing the same
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN102258485A (zh) * 2011-01-11 2011-11-30 北京润德康医药技术有限公司 一种含对乙酰氨基酚的注射用制剂及其应用
CN102600068A (zh) * 2011-01-24 2012-07-25 联康药业克雷恩特塞提斯制药实验室有限责任公司 稳定即用的可注射扑热息痛制剂

Also Published As

Publication number Publication date
CO2017006268A2 (es) 2017-10-20
ECSP17038668A (es) 2017-12-01
AU2015365533A1 (en) 2017-07-06
MA40599A1 (fr) 2017-11-30
UA122136C2 (uk) 2020-09-25
WO2016097899A1 (en) 2016-06-23
JP2017538762A (ja) 2017-12-28
PH12017501005A1 (en) 2017-12-11
BR112017012975B1 (pt) 2023-09-26
TWI649097B (zh) 2019-02-01
TN2017000232A1 (en) 2018-10-19
IL252729A0 (en) 2017-08-31
CU20170088A7 (es) 2018-03-13
JO3689B1 (ar) 2020-08-27
MD20170071A2 (ro) 2017-09-30
CA2969303A1 (en) 2016-06-23
SG11201704435PA (en) 2017-06-29
KR20170099911A (ko) 2017-09-01
MX2017008264A (es) 2017-10-02
AR103188A1 (es) 2017-04-19
US20180000940A1 (en) 2018-01-04
CL2017001629A1 (es) 2018-03-16
EA201791409A1 (ru) 2017-10-31
UY36466A (es) 2016-07-29
EP3233055A1 (en) 2017-10-25
TW201622703A (zh) 2016-07-01
BR112017012975A2 (pt) 2018-02-27
CN107205924A (zh) 2017-09-26
PE20171305A1 (es) 2017-09-05

Similar Documents

Publication Publication Date Title
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
AR107014A1 (es) Formulación farmacéutica acuosa
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
CY1118826T1 (el) Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate
AR098386A1 (es) Formulación para gonadotropinas
DOP2017000134A (es) Formulaciones inyectables de paracetamol
PE20170426A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
TN2014000464A1 (en) Parenteral esmolol formulation
EA201391512A1 (ru) Твердая фармацевтическая композиция
RU2013142835A (ru) Способ лечения ишемического инсульта
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом
EA201600331A1 (ru) Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения
RU2013143983A (ru) Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота
EA201992500A3 (ru) Соли и пролекарства 1-метил-d-триптофана
TH154084A (th) สารละลายอะเซทามิโนเฟนที่ฉีดได้สำหรับการให้ทางไขสันหลัง
ECSP15000500A (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal
TH155633A (th) สูตรผสมแบบฉีดของเอสโมลอล
TH180780A (th) สารละลายขยายม่านตา และต้านอาการอักเสบที่เสถียร ที่ปลอดจากสารกันบูด สำหรับการฉีด
RU2013119140A (ru) Способ лечения вегетососудистой дистонии у детей и подростков